Why carry out this study?

Type 2 diabetes (T2D) is increasing at an alarming rate in geriatric populations, and treatment in these patients is complex because of comorbidities and functional impairments, and a high risk of adverse events such as recurring hypoglycemia.

Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are considered a good therapy for the elderly patients with diabetes owing to its low risk of hypoglycemia.

The present study is a post hoc analysis of AWARD-CHN1 and AWARD-CHN2 to evaluate efficacy and safety of once-weekly dulaglutide (1.5 and 0.75 mg) in patients with T2D aged ≥ 60 and < 60 years.

What was learned from the study?

The study indicated a similar change in HbA1c, FBG, and weight reduction and increased proportion of patients achieving HbA1c target (< 7%) in Chinese patients in both age groups (≥ 60 and < 60 years). Incidence of GI TEAEs and hypoglycemia were low.

The overall findings from the present study demonstrate improvement of glycemic control and tolerability of once-weekly dulaglutide in patients aged ≥ 60 and < 60 years.